All In Biotech

Drug Trial Radar · NCT02187055

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Jun 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,152

Actual

Start

Aug 2014

Primary completion

Dec 2016

Study completion Dec 2016

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab. To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or adalimumab.

Conditions

  • Rhematoid Arthritis

Interventions

  • Tofacitinib with methotrexateDrug

    Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months

  • Tofacitinib without methotrexateDrug

    Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months

  • Adalimumab with methotrexateBiological

    Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6Time frame: Month 6

Locations

215 sites in 25 countries. Site status is shown where the registry gives one.

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama

  • Arthrocare, Arthritis Care & Research, PC

    Gilbert, Arizona

  • Medvin Clinical Research

    Covina, California

  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare

    Fullerton, California

  • HealthCare Partners Medical Group

    Huntington Beach, California

  • Keck Medicine of USC - Division of Rheumatology

    Los Angeles, California

  • University of Southern California (USC) Norris Comprehensive Cancer Center

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center - Drug Information Center

    Los Angeles, California

  • UCLA David Geffen School of Medicine, Division of Rheumatology

    Los Angeles, California

  • Medvin Clinical Research

    Placentia, California

  • San Diego Arthritis Medical Clinic

    San Diego, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • Medvin Clinical Research

    Van Nuys, California

  • Medvin Clinical Research

    Whittier, California

  • Joao M. A. Nascimento

    Bridgeport, Connecticut

  • AARDS Research, Inc.

    Aventura, Florida

  • Arthritis and Rheumatic Disease Specialties

    Aventura, Florida

  • Riverside Clinical Research

    Edgewater, Florida

  • Centre for Rheumatology, Immunology and Arthritis

    Fort Lauderdale, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Omega Research Consultants, LLC

    Orlando, Florida

  • Arthritis Center, Inc.

    Palm Harbor, Florida

  • Gulf Region Clinical Research Institute Llc

    Pensacola, Florida

  • West Broward Rheumatology Associates, Inc.

    Tamarac, Florida

  • BayCare Medical Group Inc

    Tampa, Florida

  • The Center for Arthritis and Rheumatism

    Vero Beach, Florida

  • The Office of Alastair C. Kennedy, MD

    Vero Beach, Florida

  • Advanced Clinical Research of Orlando, Inc.

    Winter Garden, Florida

  • Coeur D'Alene Arthritis Clinic

    Coeur d'Alene, Idaho

  • Institute of Arthritis Research

    Idaho Falls, Idaho

  • Deerbrook Medical Associates

    Vernon Hills, Illinois

  • Diagnostic Rheumatology and Research PC

    Indianapolis, Indiana

  • Ochsner Clinic Baton Rouge

    Baton Rouge, Louisiana

  • Arthritis and Diabetes Clinic, Inc

    Monroe, Louisiana

  • Arthritis Treatment Center

    Frederick, Maryland

  • Jasper Clinic

    Kalamazoo, Michigan

  • Arthritis and Osteoporosis Treatment and Research Center

    Flowood, Mississippi

  • Clinvest/ A Division of Banyan Group, Inc.

    Springfield, Missouri

  • St. Louis Center For Clinical Research Barbara Caciolo, MD

    St Louis, Missouri

  • Dr. Prem C. Chatpar M.D.,LLC

    Plainview, New York

Showing 40 of 215 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.